Novo Nordisk's weight loss drug Novo Ying has made new progress in its domestic listing.

Today, Novo Nordisk announced that the world's first and currently the only long-term weight management glucagon-like peptide-1 receptor agonist (GLP-1) weekly preparation Novo Ying has officially launched in China.

Novo Ying, also known as the "weight loss version" of semaglutide, can achieve an average weight reduction of approximately 17%, and its weight loss effect can last for at least 2 years.

Novo Nordisk revealed that currently, Novo Ying has been launched in over 10 countries and regions worldwide.

As of now, semaglutide has accumulated over 22 million patient exposure years of use.

Some private medical institutions in Shanghai have indicated that Novo Ying has arrived, with a considerable number of inquiries from customers. At the same time, Novo Ying can be found for sale on various platforms such as Meituan, Taobao, and JD.com.

In June this year, Novo Nordisk announced that the National Medical Products Administration approved the marketing application of Novo Nordisk's developed and manufactured Nohewing (semaglutide injection for long-term weight management) in China.

This drug is the first domestically approved injectable drug for weight loss indications, and is expected to be gradually launched in mid-November. The first batch of drugs will enter designated hospitals, pharmacies, weight loss centers, etc.

Previously, Novo Nordisk's semaglutide injection was approved for its glucose-lowering indication domestically in 2021.

Subsequently in July, competitor Eli Lilly's tirzepatide injection (trade name: Mufengda) obtained approval from the National Medical Products Administration for a new indication for long-term weight management.

The domestic market has huge potential.

With the rapid development of social economy and the improvement of people's living standards, the obese population is increasing, leading to a rising demand in China for weight loss drugs.

According to Frost & Sullivan statistics, the number of obese people in China increased from 0.19 billion in 2017 to 0.23 billion in 2021, and is projected to reach 0.33 billion by 2030.

Obesity may increase the risk of diseases such as coronary heart disease, diabetes, and hypertension. With the increasing obese population and the enhanced awareness of weight management among residents, the GLP-1 weight loss market is expected to grow rapidly.

Therefore, the weight loss drug market has broad prospects.

On a global scale, Goldman Sachs' analysis team has raised the global weight loss drug market size for 2030 from $100 billion at the end of last year to $130 billion.

Looking domestically, Founder Securities predicts that by 2030, the domestic GLP-1 weight loss drug market is expected to exceed 37.852 billion yuan.

In addition, weight loss drugs have a strong consumer attribute, mainly relying on individual payment, with little impact from medical insurance.

In terms of investment, Anxin International believes that since two imported weight loss drugs have been approved and launched in China this year, the Chinese weight loss market is expected to enter a high-growth phase. It is recommended to focus on related symbols in the GLP-1 weight loss industry chain, individual stocks such as API manufacturers like Nuote Biotech; innovative drug companies with advanced research and development, such as Innovent Bio, Jiangsu Hengrui Pharmaceuticals, etc.

Founder Securities suggests focusing on API layout companies: pay attention to Nuote Biotech, hybio pharmaceutical, Shengnuo Biotechnology, aurisco pharmaceutical, etc.; CDMO: pay attention to asymchem laboratories, zhejiang jiuzhou pharmaceutical; innovative drug layout pharmaceutical companies: focus on jiangsu hengrui pharmaceuticals, brightgene bio-medical technology co.,ltd., innovent bio, lepu medical technology, guangdong zhongsheng pharmaceutical, etc.